Our distinctive medical research programme regularly funds ovarian cancer-specific research across the whole of the UK. We fund innovative research that will benefit the largest proportion of women with ovarian cancer in the shortest timeframe.
In a short period of time, we have developed a reputation as a funder of high quality research to benefit women with ovarian cancer. We have already committed over £1.25 million to nine outstanding projects through our translation research awards for new treatments. These projects are:
- Developing new treatments for low grade serous ovarian cancer
- Unlocking the power of the immune system
- Circulating tumour DNA as a specific diagnostic biomarker for ovarian cancer
- Genetic testing in epithelial ovarian cancer (GTEOC) study
- Targeting microtubules to overcome resistance to chemotherapy drugs
- Personalised therapy in ovarian cancer: targeting flap structure specific endonuclease (FEN1)
- Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma
- EDMONd: diet and nutrition for patients with inoperable malignant bowel obstruction
- Palliative chemotherapy to manage symptoms in women with recurrent ovarian cancer
- Translating our knowledge of the DNA damage response into clinical benefits for patients with ovarian cancer
Target Ovarian Cancer does not receive any government funding. This research is only made possible through donations and legacies. If you would like to contribute to these research projects and improve treatments for women with ovarian cancer, please support us.